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Abstract
Background: Intensive medical care in companion animal clinics could pose a risk for the selection and dissemination
of multidrug-resistant organisms (MDROs). Infection prevention and control (IPC) concepts are key measures to reduce
the spread of MDROs, but data on IPC standards in companion animal clinics is sparse. The study assessed IPC
standards in seven companion animal clinics and practices in Switzerland by structured IPC audits and combined
results with environmental MDRO contamination and MDRO carriage of the personnel.
Methods: IPC audits were held between August 2018 and January 2019. The observations in 34 IPC areas were scored
based on predefined criteria (not fulfilled/partially fulfilled/fulfilled = score 0/1/2). Environmental swabs and nasal and
stool samples from veterinary personnel were tested for methicillin-resistant (MR) staphylococci and macrococci and
for colistin-resistant, extended-spectrum β-lactamase- and carbapenemase-producing (CP) Enterobacterales (CPE).
Species was identified by MALDI-TOF MS, antimicrobial resistance determined by microdilution and β-lactam resistance
gene detection, and genetic relatedness assessed by REP−/ERIC-PCR and multilocus sequence typing.
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Results: Of a maximum total IPC score of 68, the institutions reached a median (range) score of 33 (19–55). MDROs
were detected in median (range) 8.2% (0–33.3%) of the sampling sites. Clinics with low IPC standards showed
extensive environmental contamination, i.e. of intensive care units, consultation rooms and utensils. CPE were detected
in two clinics; one of them showed extensive contamination with CP Klebsiella pneumoniae (ST11, blaOXA-48) and MR
Staphylococcus pseudintermedius (ST551, mecA). Despite low IPC scores, environmental contamination with MDROs was
low in primary opinion practices. Three employees were colonized with Escherichia coli ST131 (blaCTX-M-15, blaCTX-M-27,
blaCTX-M-14). Two employees carried CP E. coli closely related to environmental (ST410, blaOXA-181) and patient-derived
isolates (ST167, blaNDM-5). MR Staphylococcus aureus (ST225, mecA) and MR S. pseudintermedius (ST551, mecA) of the
same sequence types and with similar resistance profiles were found in employees and the environment in two clinics.
Conclusions: The study indicates that IPC standards in companion animal clinics are variable and that insufficient IPC
standards could contribute to the evolution of MDROs which can be transferred between the environment and
working personnel. The implementation of IPC concepts in companion animal clinics should urgently be promoted.
Keywords: Infection prevention and control, Small animal clinic, Enterobacteriaceae, Antimicrobial resistant pathogens,
Multidrug-resistant pathogens, Colonization, Zoonosis
Background
Antimicrobial resistance (AMR) is an increasing chal-
lenge in human and veterinary health care and an emer-
ging threat for public health [1]. Because multidrug-
resistant (MDR) organisms (MDROs) are exchanged be-
tween humans, animals and the environment, the com-
bat of AMR needs to be done under a One Health
approach [2]. In addition to antimicrobial misuse and
overuse in human and veterinary medicine, health care-
associated transmission is regarded as a third main
driver in the development and spread of AMR [3]. Infec-
tion prevention and control (IPC) concepts are well
established in human health care settings to reduce the
risk of transmission and spread of MDROs [4].
Progress in the area of small animal intensive care has
led to the establishment of large specialized clinics in in-
dustrial countries in Europe, the United States and Asia.
In these settings, the development and transmission of
MDROs is facilitated by: 1) the high density of patients
susceptible for infections, 2) daily invasive health care in-
terventions, 3) the high percentage of patients receiving
antimicrobial therapy, and 4) the use of last-generation
and highest priority critically important antimicrobials [5,
6]. Accordingly, outbreaks with methicillin-resistant (MR)
Staphylococcus aureus (MRSA) and Staphylococcus pseu-
dintermedius (MRSP) or highly resistant Acinetobacter
spp. isolates in small animal clinics in Europe have been
documented [7–10]. Most recently, an outbreak involving
CP Escherichia coli was reported in a large companion
animal clinic in Switzerland [11]. Because of the close con-
tact of dogs and cats with their owners [12], the acquisi-
tion of MDROs by companion animals could pose a
considerable risk to humans [13–15]. Zoonotic transmis-
sion of MDROs from pets to humans have been proposed
for MRSA, MRSP, and extended-spectrum β-lactamase
(ESBL) and carbapenemase-producing (CP)
Enterobacterales (CPE) [16–22]. Furthermore, MR
coagulase-negative staphylococci (MRCoNS) with the
same pulsed-field gel electrophoresis patterns were found
in horses, personnel and environmental sites in an equine
hospital in Denmark [23]. This finding suggests that
MRCoNS strains can be shared between horses and
personnel. MRCoNS represent an emerging cause of op-
portunistic infections in humans [24], and infections with
MRCoNS have been documented in companion animals
[25]. Recently, a novel Macrococcus spp., namely Macro-
coccus canis, has been isolated from healthy dogs and
from infection sites of dogs; some isolates exhibited a
MDR pattern [26, 27]. M. canis was found to have the
ability to acquire AMR including methicillin resistance
[28], but the potential contamination of the clinical envir-
onment with MR Macrococcus spp. has not yet been
assessed.
Despite the key role of IPC concepts in limiting the
dissemination of MDROs in human health care settings,
data on IPC standards in companion animal veterinary
institutions is sparse. The aim of the present prospective
study was to evaluate IPC standards in different types of
companion animal clinics and practices in Switzerland
using structured IPC audits. Results were combined with
investigations of the clinical environment and working
staff for the presence or carriage of MR staphylococci,
ESBL-producing, CP and colistin-resistant (COL-R)
Enterobacterales and MR Macrococcus spp.
Methods
Aim, study design and IPC audits
The present prospective study was part of a large
nation-wide project assessing the role of companion ani-
mal clinics in the dissemination of MDROs.
Three large clinics (A–C), two medium-sized clinics
(D–E) and two first opinion practices (F–G) for
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companion animals were recruited. The institutions
were chosen to be located in different parts of
Switzerland and to cover different clinic/practice types
(Additional file 1). One structured one-day audit per
clinic or practice was performed between August 2018
and January 2019 by infectious disease specialists from
human and small animal medicine to evaluate IPC stan-
dards. The audits covered 11 areas and 34 topics of IPC
in small animal veterinary medicine [29, 30] and the ob-
servations were recorded and scored based on the cri-
teria specified in Additional file 2. A score per IPC area
and a total IPC score were calculated for each compan-
ion animal clinic and practice. Participation in the study
was voluntary and was not reimbursed. The participating
clinics and practices received a written report of the au-
dits with suggestions for areas of improvements.
Environmental sample collection
Samples from high-touch surfaces were collected in the
institutions between June and November 2018. Sample
collection was performed during a one-day visit from a list
of high-touch surfaces (Additional file 3) including 69
sampling sites in large clinics (A–C) and 49 sampling sites
in medium-sized clinics and practices (D–G). Differences
in the number of resulting sampling sites at the different
institutions were due to differences in infrastructure. The
sampled surfaces were not disclosed prior to sampling.
Samples were collected using transport swabs with
enclosed tube containing Amies transport medium (Sar-
stedt AG & Co. KG, Nümbrecht, Germany). Environmen-
tal samples were tested for MRSA, MRSP, MRCoNS, MR
Macrococcus spp., and ESBL-producing, CP and COL-R
Enterobacterales (see below). In Clinic B, an additional 58
swabs were collected by the staff of the clinic in August
2018 from known high-risk areas (emergency room, n =
17; intensive care unit (ICU), n = 25; wards, n = 10; con-
sultation room, n = 1; elevator, n = 1; lingerie, n = 2;
entrance, n = 1; thermometers (10 pooled), n = 1) and ana-
lyzed specifically for CP Enterobacterales.
Sample collection from employees
Veterinary employees in Clinics A–C and Practice G
were recruited for the study and instructed by an infor-
mation session held at the according institution. Partici-
pating staff self-collected a stool and a mid-turbinate
nasal sample using a sampling kit (swabs and transport
tubes containing Amies transport medium, Sarstedt AG
& Co. KG; stool sample collection kit, Novoglas Labor-
technik Langenbrinck, Niederrohrdorf, Switzerland). The
samples were put into a transport container and sent to
the Institute for Infectious Diseases, University of Bern,
Switzerland for analysis. Nasal swabs were analyzed for
MRSA, MRSP and MRCoNS, and the stool samples for
COL-R Enterobacterales, and ESBL-producing and CP
Enterobacterales as described below. The participants
filled a questionnaire to obtain data on age, sex, clinic/
practice type, working division and position, working du-
ties, pet ownership, diet, medical history, medical and
antibiotic treatment in the past, contact to the human
health care system and to MDRO-carriers, and leisure
and travel activities in order to evaluate risk factors for
MDRO carriage. The questionnaire was pre-labelled
with the pseudonymization number.
Isolation and identification of the strains
MRSA, MRSP, MRCoNS and MR Macrococcus spp.
were cultured using a two-step enrichment procedure
and selected on chromogenic selective MRSA agar plates
(BBL CHROMagar MRSA II, Becton Dickinson GmbH,
Heidelberg, Germany) [31].
COL-R, 3rd generation cephalosporin-resistant and
carbapenem-resistant Enterobacterales including E. coli
and Klebsiella spp. were isolated after overnight enrich-
ment in Luria-Bertani broth on specific selective plates
including ChromID ESBL, ChromID CARBA SMART
(bioMérieux, Suisse S.A., Geneva, Switzerland), and
CHROMAgar plates supplemented with Colistin (bio-
Mérieux). Colonies were purified onto MacConkey II
Agar (Becton Dickinson GmbH) and identified to the
species level by matrix-assisted laser desorption/
ionization time-of-flight mass spectrometry (MALDI-
TOF MS) analysis (Microflex LT, Bruker Daltonics
GmbH, Bremen, Germany).
Antibiotic susceptibility testing and strain typing
Antimicrobial susceptibility was determined by the meas-
urement of the minimal inhibitory concentrations (MICs)
of different antibiotics by broth microdilution using Sensi-
titre EUST, EUVSEC, EUVSEC2 and GNX2F plates
(Thermo Fisher Scientific, Waltham, USA). For Staphylo-
coccus and Macrococcus species, MICs of 18 antimicro-
bials as specified in Table 1 were determined. MIC results
were interpreted using the European Committee on Anti-
microbial Susceptibility Testing (EUCAST) criteria [32],
except for kanamycin and sulfamethoxazole, for which the
Clinical and Laboratory Standards Institute (CLSI) criteria
were used [33]; no clinical breakpoints were available for
streptomycin. For the Enterobacterales, MICs of 14 anti-
microbials as specified in Table 2 were determined. MIC
results were interpreted using the EUCAST criteria [32],
except for nalidixic acid, sulfamethoxazole and tetracyc-
line, for which criteria from the CLSI were used [33]; no
clinical breakpoints were available for azithromycin. The
methicillin resistance genes mecA, mecB, and mecD were
identified by PCR as previously described [34–36]. The
ESBL and carbapenemase genes were identified using the
CT103XL microarray (Check-Points, Wageningen, The
Netherlands). Genetic relationships and clonality between
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isolates of the same species were determined by REP
−/ERIC-PCR [37, 38] and by multilocus sequence typing
(MLST) for MRSA, MRSP, MRCoNS, MR Macrococcus
spp. using the corresponding schemes published in the
PubMLST database (https://pubmlst.org/databases/) and
for COL-R, ESBL-producing and CP Enterobacterales
using the Center for Genomic Epidemiology (http://www.
genomicepidemiology.org/).
Data analysis
Data from employees were collected and managed using
REDCap (Research Electronic Data Capture) hosted at
the University of Bern, Switzerland [39, 40]. Statistical
analysis was performed using SPSS version 24.0.0. (IBM,
Zurich, Switzerland) and the freely available software
program R version 3.2.0 [41]. A total of 26 categorical
parameters were statistically analyzed for association
with carriage of Gram-positive or Gram-negative
MDROs in employees using the Chi square and Fisher’s
exact test (for expected frequencies < 5). P-values < 0.05
were considered statistically significant.
Results
IPC audit scores
Five small animal clinics and two first opinion practices
from Switzerland participated in the study (Additional
file 1). Of a maximum total IPC score of 68, the clinics/
practices reached a median (range) total IPC score of
33 (19–55) (Table 3). Major IPC deficits in the institu-
tions were absence of written IPC manuals (4/7 institu-
tions), absence of regular IPC audits (7/7 institutions),
absence of written and updated protocols for cleaning
and disinfection (4/7 institutions), absence of written
protocols for quarantine measures (6/7 institutions) and
no definition and flagging of patients with MDROs (5/7
institutions, Additional file 4).
Environmental contamination with MDROs
Results for environmental contamination with MDROs
in the Clinics A–C and Clinics/Practices D–G are shown
in Tables 4 and 5, respectively. Details on species, strains
and antibiotic resistance profiles of the Gram-positive
and Gram-negative isolates are given in Tables 1 and 2,
respectively. Overall, MDROs were found in median
(range) 8.2% (0–33.3%) of the environmental sampling
sites in the seven institutions; consultation rooms, ICUs
and utensils were most commonly contaminated. In the
additional samples collected in Clinic B, 22% tested posi-
tive for CP K. pneumoniae (ST11, blaOXA-48, n = 13);
samples from the emergency room and ICU accounted
for 12/13 positive samples. The results of the IPC scor-
ing in the clinics were in accordance with the extent of
environmental contamination. Clinics B, C and E with
scores of 35, 33 and 19, respectively, showed most
extensive environmental contamination, with 30, 32 and
33% of the sampling sites testing positive for MDROs,
respectively (Tables 3, 4 and 5).
In Clinic B, the environment was highly contaminated
with MRSP (ST551, mecA) and CP K. pneumoniae
(ST11, blaOXA-48); CP E. coli (ST410, blaOXA-181;
ST4038, blaOXA-48) were found in single sampling sites
(Tables 1 and 2). All 16 MRSP (ST551, mecA) isolates
showed similar resistance profiles (Table 1). The total 18
CP K. pneumoniae (ST11, blaOXA-48) isolates from the
two sample collections in Clinic B also shared similar
resistance profiles (Table 2) and showed the same REP-
PCR profile (data not shown). In Clinic C, the environ-
ment was highly contaminated with MRCoNS (Table 1).
Thirteen MR Staphylococcus haemolyticus isolates (ST9,
mecA) were detected which showed similar resistance
profiles (Table 1); 11 and 2 S. haemolyticus isolates
showed the same ERIC-PCR profiles, respectively (data
not shown). In Clinic E, a diverse population of MDROs
was found, predominated by MR Macrococcus spp.
(ST69, mecB; ST71, mecB–D; ST35, ST38, ST72, mecD)
and S. haemolyticus (ST30, ST42, ST69, mecA) isolates
(Table 1); a single CP E. coli (blaOXA-48) isolate was de-
tected in a consultation room (Table 2). The MR S. hae-
molyticus isolates in Clinic E showed no clonal
relationship in ERIC-PCR (data not shown) and different
antibiotic resistance profiles (Table 1).
MDRO colonization of employees
A total of 109 employees of Clinics A–C and Practice G
provided samples (99 nasal swabs and 108 fecal samples)
and 108 employees completed the questionnaire. Results
for MDRO carriage in employees are shown in Table 6,
details on the detected Gram-positive and Gram-
negative isolates are shown in Tables 1 and 2,
respectively.
A total of 13 (13%) of the employees carried MR
Staphylococcus spp., comprising 7 genetically diverse
MRSA (ST398, ST7, ST45, ST97, ST5, ST225; mecA),
one MRSP (ST551, mecA) and five MR S. epidermidis
isolates. MR Staphylococcus spp. of the same sequence
types and with similar AMR profiles were found in both
employees and the environment in Clinic B (MRSP
ST551) and Clinic C (MRSA ST225) (Table 1); no data
on antibiotic resistance profiles and sequence typing
were available for the MR S. epidermidis isolates. Car-
riage of MR Staphylococcus spp. was associated with the
presence of an actual disease (p = 0.036) and contact to
horses during work (p = 0.049). Actual diseases listed by
employees with carriage of MR Staphylococcus spp.
were: cystitis (n = 1), chronic sinusitis (n = 2) and Mor-
bus Basedow (n = 2).
A total of 6 (6%) and 7 (7%) employees tested positive
for ESBL-producing and COL-R Enterobacterales,
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respectively. There was no evidence for clonal relation-
ship of these isolates based on sequence type, antibiotic
resistance profiles (Table 2) and REP-PCR (data not
shown). Three employees were colonized with E. coli
ST131 (blaCTX-M-15, blaCTX-M-27, blaCTX-M-14, Table 2).
Two staff members were found to be carriers of CP E.
coli; details of these isolates have been published [42]. A
staff member in Clinic A carried a CP E. coli (ST167,
blaNDM-5, blaCMY-2, blaTEM-30). In Clinic B, a staff mem-
ber showed fecal carriage of a CP E. coli (ST410,
blaOXA-181, blaCMY-42) isolate that was closely related to
an isolate from the environment [42]. A significant asso-
ciation of carriage of Gram-negative MDROs was found
for living in an urban environment (p = 0.026) and lack
of outdoor activities (p = 0.017).
Discussion
This study documents variable IPC standards in com-
panion animal clinics and practices in Switzerland and
extensive contamination with MDROs in institutions
with low IPC standards. Worryingly, CP Enterobacter-
ales were detected in the environment of two compan-
ion animal clinics, one of them showing extensive
contamination with both CP K. pneumoniae (ST11,
blaOXA-48, blaDHA-1) and MRSP (ST551, mecA). The re-
sults of the study suggest that insufficient IPC standards
in companion animal clinics are associated with environ-
mental contamination with MDROs and may increase
the risk of potential transfer of MDR bacteria between
the clinical environment, patients and employees. In this
context, two employees in this study were found to be
colonized with CP E. coli closely related to environmen-
tal or patient-derived isolates [43], and two staff mem-
bers carried MRSA and MRSP of the same sequence
type as found in the environment in the according insti-
tution, respectively; some of these results have been pub-
lished [11, 42]. CPE have been classified as an “urgent”
public health threat by the US Centers for Disease Con-
trol and Prevention because nosocomial infections in
humans have been associated with a case fatality rate of
up to 50% [44, 45]. Carbapenems are used as a last-
resort therapy for invasive Gram-negative infections in
humans [46]. Although not licensed for use in animals,
they have been reported to be used occasionally in dogs
and cats [5]. Interestingly, carbapenems have never been
used in patients of Clinic B, suggesting that the develop-
ment and clonal spread of the CPE in the environment
of this clinic was not driven by selection pressure
exerted by carbapenems [11].
Several deficits in IPC could have contributed to the
extensive spread of MRSP and CPE in Clinic B. The
clinic had no written protocols on cleaning and disinfec-
tion in place. Disposable gloves were worn at every pa-
tient contact and routine hand disinfection was
inconsistently performed. Utensils such as scissors or
clippers were personalized to the staff members and car-
ried in personal bum bags. This carries the risk of con-
tamination of the utensils within the bags which could
than act as vehicles to transfer MDROs between pa-
tients. In Switzerland, like in many other European
Table 3 Infection prevention and control scores of the seven small animal clinics/practices
Area of IPCa Maximum
score
Institution Sum per
area for the
evaluated
institutions
Maximum
sum per area
for seven
institutions
Clinic A Clinic B Clinic C Clinic D Clinic E Practice F Practice G
IPC management 6 4 2 4 2 0 0 2 14 42
Staff education 6 5 4 3 5 0 0 0 17 42
Cleaning / disinfection 6 5 2 2 6 3 3 4 25 42
Quarantine measures 6 6 1 2 3 1 3 0 16 42
Guidelines for patients
with MDROs
4 3 3 1 1 0 1 0 9 28
Hand hygiene 8 7 3 5 8 2 6 3 34 56
Personal hygiene 12 9 7 5 9 3 6 2 41 84
Protection of employees 4 2 3 2 1 3 3 2 16 28
Protective clothing 6 6 4 4 4 3 4 0 25 42
Medication 6 4 2 5 6 3 3 6 29 42
Guidelines/restrictions
for antimicrobial use
4 4 4 0 3 1 4 1 17 28
Total score 68 55 35 33 48 19 33 20 243 476
% of maximum score 100% 81% 52% 49% 71% 28% 49% 29% 51% 100%
aThe total score per IPC area is shown. For detailed scoring see Additional file 4
Abbreviations: IPC Infection prevention and control, MDROs multidrug resistant organisms
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Table 4 Results of environmental examinations for multidrug-resistant organisms in Clinics A–C
Area Clinic Aa Clinic Ba Clinic Ca
No. of sampling
sitesb
MRS ESBL-PE No. of sampling
sitesb
MRS ESBL-PE CPE Macrococcus spp. No. of sampling
sitesb
MRS
Waiting area 3 1 0 3 0 0 0 0 3 1
Consultation rooms 6 0 0 6 5 0 2 1 3 0
ICU 4 2 0 6 5 0 4 0 6 4
Radiology 3 0 0 3 0 0 0 0 1 1
Ward 3 0 1 4 1 0 2 0 3 1
Quarantine ward 1 0 0 3 0 0 0 0 3 2
Pre-OR area 7 1 0 6 0 0 0 0 6 1
OR 10 0 0 10 0 0 0 0 10 0
Laboratory 4 0 0 4 1 0 0 0 3 1
Endoscopy 1 0 0 1 0 0 0 0 1 0
Dental room 3 0 0 3 0 0 0 0 2 0
Utensilsc 9 0 0 9 3 0 0 0 8 5
Othersd 7 0 0 8 2 1 0 0 4 2
Total no. of
sampling sites
61 66 53
Total no. (%) of
positive sampling sites
5 (8) 4 (7) 1 (2) 20 (30) 17 (26) 1 (2) 6 (9)e 1 (2) 17 (32) 17 (32)f
a Results for all included multidrug-resistant organisms are shown (Methicillin-resistant staphylococci, ESBL- and carbapenemase-producing Enterobacterales and
Macrococcus spp.); missing rows indicate no positive result for this group of multidrug-resistant organisms. Positive results are shown in bold. Details on species,
strain and minimal inhibitory concentrations of the isolates are specified in Tables 1 and 2. bDetails on sampling sites are indicated in Additional file 3. cUtensils:
transport boxes, transport trolleys, mobile phones / pagers, stethoscopes, thermometers, otoscopes, clippers, ultrasonography devices, scissors / clamps, sharp
drops. dOthers: elevator, bath, feeding kitchen, lingerie, staff toilet, pneumatic dispatch system. eIn two sampling sites, two different isolates were found. fIn one
sampling site, two different isolates were found. Abbreviations: MRS Methicillin-resistant staphylococci, ESBL-PE Extended spectrum ß-lactamase-producing
Enterobacterales, CPE carbapenemase-producing Enterobacterales, ICU intensive care unit, OR operating room
Table 5 Results of environmental examinations for multidrug-resistant organisms in Clinics/Practices D–G
Area Clinic Da Clinic Ea Practice Fa Practice Ga
No. of sampling
sitesb
All MDROs
tested
No. of sampling
sitesb
MRS CPE Macrococcus
spp.
No. of sampling
sitesb
MRS No. of sampling
sitesb
MRS
Waiting area 2 0 2 1 0 0 2 0 2 1
Consultation rooms 4 0 5 1 1 2 5 2 5 0
Radiology 1 0 2 0 0 1 2 0 1 2
Ward 4 0 5 1 0 1 7 0 6 0
Pre-OR area 4 0 4 1 0 1 4 0 2 0
OR 7 0 4 0 0 0 3 0 5 0
Laboratory 3 0 4 1 0 0 5 0 4 0
Office 2 0 1 0 0 0 2 0 0 0
Utensilsc 8 0 8 1 0 2 8 0 8 0
Othersd 3 0 4 0 0 1 2 0 4 0
Total no. of
sampling sites
38 39 40 37
Total no. (%) of
positive sampling sites
0 (0) 0 (0) 13 (33) 6 (15) 1 (3) 8 (21) 2 (5) 2 (5) 3 (8) 3 (8)
a Results for all included MDROs are shown (Methicillin-resistant staphylococci, ESBL- and carbapenemase-producing Enterobacterales and Macrococcus spp.);
missing rows indicate no positive result for this group of MDROs. Positive results are shown in bold. Details on species, strain and minimal inhibitory
concentrations of the isolates are specified in Tables 1 and 2. bDetails on sampling sites are indicated in Additional file 3. cUtensils: phones, stethoscopes,
thermometers, otoscopes, clippers, ultrasonography devices, clamps / scissors, muzzles, dental cleaning devices / utensils. dOthers: feeding utensils, lingerie,
changing rooms, sterilizer
Abbreviations: MDROs multidrug resistant organisms, MRS Methicillin-resistant staphylococci, CPE carbapenemase-producing Enterobacterales, OR operating room
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countries, no legislation regulates the IPC standards in
small animal veterinary clinics and practices. Further-
more, education of veterinary students and practicing
veterinarians in IPC is hampered by a lack of IPC spe-
cialists and training programs in companion animal
medicine [47]. Immediately after the discovery of the
outbreak in Clinic B, a comprehensive IPC concept was
implemented with the support of IPC professionals,
hand disinfection dispensers were placed throughout the
clinic and hand hygiene training has been initiated for
all employees.
Overall, the IPC standards found in the companion
animal clinics in Switzerland were variable. The deficits
in IPC were illustrated by i.e. the absence of written IPC
manuals in 4/7 institutions, no staff education on any
IPC-related topics in 3/7 institutions, no definition and
flagging of MDRO patients in 5/7 institutions, and no
written and updated protocols on quarantine measures
in 6/7 institutions. Clinic E with the lowest total IPC
score had no IPC management in place at all, no hand
sanitizers and dispensers were available throughout the
clinic and no guidelines for the handling of patients with
MDROs were established.
Antimicrobial use is thought to be a major driving
force towards antimicrobial resistance [3]. The IPC au-
dits in this study assessed whether specified guidelines
on the use and dosing of antimicrobials were available
for all employees involved in prescription and applica-
tion of antimicrobials, and whether use of antibiotics of
last resort were restricted and limitations communicated
and known to all employees; these aspects were com-
pletely fulfilled by 4/7 and 3/7 institutions, respectively.
However, overall consumption of antimicrobials was not
assessed because this data was not collected and moni-
tored by the investigated institutions. An information
system for antimicrobials (IS ABV) to monitor their con-
sumption in all veterinary clinics and practices in
Switzerland was introduced by the Swiss Federal Food
Safety and Veterinary Office in October 2019 [48], after
conclusion of this study, but reliable data from the sys-
tem is not yet available.
Four institutions (A–D) included in the present study
were recently evaluated for antimicrobial prescription
habits in dogs and cats in two unrelated studies [49, 50].
In these investigations, the frequency of prescription and
adherence to prudent use guidelines for three disease
complexes in cats and four disease complexes in dogs
were evaluated between January and December 2016.
There was no difference in overall prescription rate
among Clinics A–D for the evaluated cases (247 feline
and 431 canine cases; BW and SS, personal communica-
tion). We therefore assume that overall antibiotic use
was not a major contributor to the differences in envir-
onmental contamination with MDROs observed in
Clinics A–D.
Whether the extensive environmental contamination
poses a nosocomial infection risk for the patients in
these institutions cannot be answered from this study.
None of the evaluated institutions had an active surveil-
lance of health care-associated infections in place. How-
ever, retrospective investigations to assess the role of
CPE in nosocomial infections in Clinic B are underway.
Areas with high patient traffic, such as consultation
rooms and ICUs, and utensils were most commonly
contaminated with MDROs. High rates of contamination
with MR staphylococci in high traffic areas within a vet-
erinary hospital have been documented [51]. The clonal
relationship of the MDROs in the environment of
Clinics B and C also suggests a spread from a common
source in these institutions. Practices F and G on the
other hand reached rather low IPC scores in fact, how-
ever, environmental contamination was low in both
practices. This could indicate that first opinion practices
in contrast to large referral clinics are less critical in the
Table 6 Colonization with multidrug-resistant organisms of employees of Clinics A–C and Practice G
Institution Total no. of
sampled
employees
(nasal swabs
/ fecal samples)
No. of sampled No. (%)a of employees positive for Total no. (%)b
of positive
employees
Veterinarians Nurses Others/
unknownc
MRSA MRSP MRCoNS ESBL-PE CPE CRE
Clinic A 38 (37/37) 19 12 7 4 (11) 0 (0) 2 (5) 3 (8) 1 (3) 3 (8) 12 (32)d
Clinic B 46 (38/46) 22 13 11 2 (5) 1 (3) 3 (8) 3 (7) 1 (2) 3 (7) 13 (28)
Clinic C 21 (20/21) 14 6 1 1 (5) 0 (0) 0 (0) 0 (0) 0 (0) 1 (5) 2 (10)
Practice G 4 (4/4) 1 3 0 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 109 (99/108) 56 34 19 7 (7) 1 (1) 5 (5) 6 (6) 2 (2) 7 (7) 27 (25)d
a Percentage related to total number of nasal swabs or fecal samples available from the according institution. b Percentage related to number of sampled
employees. c Profession not known for 5 participating employees. dOne employee tested positive for both an ESBL-producing and
colistin-resistant Enterobacterales
Abbreviations: MRSA methicillin-resistant Staphylococcus aureus, MRSP methicillin-resistant Staphylococcus pseudintermedius, MRCoNS methicillin-resistant coagulase-
negative staphylococci, ESBL-PE extended-spectrum β-lactamase-producing Enterobacterales, CPE carbapenemase-producing Enterobacterales, CRE
colistin-resistant Enterobacterales
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development and spread of MDROs. Studies in human
medicine suggest that the influx of resistant pathogens
varies significantly in hospitals of different size, location
and patient groups [52]. Therefore, a large clinic could
be at higher risk for the introduction of MDR pathogens
than first opinion practices [2]. Since the number of first
opinion practices included in this study was low, no con-
clusions can yet be drawn and future studies should ad-
dress the role of first opinion practices in the
development and spread of MDROs.
The prevalence of colonization with ESBL-producing
or COL-R Enterobacterales in veterinary employees in
this study was comparable to the colonization rate in the
general population in Switzerland [53, 54]. Three em-
ployees from Clinics A and B were found to be colo-
nized with E. coli ST131 (blaCTX-M-15, blaCTX-M-27,
blaCTX-M-14). E. coli ST131 is one of the most important
globally disseminated bacterial lineage and causes severe
hospital-acquired and community-onset MDR infections
in humans [55]. Infections with E. coli ST131 have,
amongst others, also been reported in companion ani-
mals [56]. Of note, an unrelated study investigated clin-
ical samples originating from canine and feline patients
from Clinic A and found that the prevalence of ESBL-
producing uropathogenic E. coli ST131 had increased
between 2010 and 2012 from 0 to 1.5%, and included E.
coli ST131 (blaCTX-M-15 and blaCTX-M-27) [57].
The prevalence of colonization with MRSA in veterinary
employees in this study was higher than reported for the
general population in Switzerland (7% vs 1.5%) [58]. Variable
MRSA sequence types were detected in the employees, in-
cluding healthcare-associated (ST225, ST5, ST45, ST7),
livestock-associated (ST398) and community-acquired
MRSA (ST97). Veterinarians have an occupational risk for
acquisition of MRSA [59]. Contact with horses has been re-
ported to be a risk factor for acquiring MRSA ST398 [60]
and was also found to be associated with colonization with
MR staphylococci in this study. Carriage of MRSP has been
well documented in veterinarians and owners with contact
to MRSP infected animals [16, 17, 21, 61, 62]. MRSP ST551
has so far only occasionally been reported in companion ani-
mals in Europe, but was found to have become the dominat-
ing MRSP lineage in dogs in Poland, but emerged not before
2015 [63]. An occupational acquisition of MRSP ST551 by
the employee in Clinic B due to extensive environmental
contamination with this clone seems most likely.
Environmental detection of macrococci was common
in this study, especially in Clinic E. The identified se-
quence types were highly variable, which was recently
also found for macrococci isolated from carriage and in-
fection sites of dogs [27]. The macrococci sequence
types found in the environment did not match the line-
ages recently documented in dogs in Switzerland [27].
The clinical significance of macrococci in companion
animals and the impact of environmental contamination
with macrococci has not yet been resolved and needs
further investigations.
Conclusions
The present study documents variable IPC standards in
companion animal clinics and practices in Switzerland.
Low IPC standards in clinics were associated with exten-
sive environmental MDRO contamination. The detec-
tion of an MRSP and CP Enterobacterales outbreak in
one clinic and of closely related MDRO isolates in em-
ployees, patients and the environment in several clinics
indicate that insufficient IPC standards in companion
animal clinics may pose a public health risk. The results
suggest that companion animal clinics can significantly
contribute to the development and dissemination of
MDROs. Proper IPC standards in small animal veterin-
ary clinics and educational programs in IPC for veterin-
ary students and practitioners should therefore urgently
be promoted.
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